Our studies indicate that disrupting the CD40–TRAF2,3 pathway may become a novel approach to inhibit inflammatory responses involved in the pathogenesis of diabetic retinopathy, and potentially other CD40-driven inflammatory diseases. The gene discussed is CD40; the disease is diabetic retinopathy.